PRDM9 and breast carcinoma: After functional analysis of the identified genes, we focused on the “Histone-lysine N-methyltransferase activity” function and found that the histone methyltransferase gene KMT2D was mutated in around 6% of the TNBCs samples evaluated; in addition to be associated with poor prognosis in this breast cancer subtype.